NewsRoom

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013

20122011201020092008

Jun 1, 2019
- Statistically significant biologic anti-tumor activity demonstrated as measured by a reduction in Ki67 in patients treated with ME-344 compared to an increase in patients receiving placebo -
May 15, 2019
International Conference on Malignant Lymphoma (ICML) Selects ME-401 Abstract for Oral Presentation
Feb 7, 2019
-- MEI Remains in Strong Position as ME-401 Advances to Global Phase 2 Study to Support FDA Accelerated Approval --
Dec 2, 2018
- Data Support Complementary Potential of Intermittent and Continuous Dosing Schedules as Means to Optimize Clinical Risk-Benefit Ratio in Relapsed/Refractory Follicular Lymphoma Patients -
Nov 8, 2018
-- MEI on Track to Initiate ME-401 Phase 2 Accelerated Approval Study Around Year-End --